ArticleEuropean journal of medical research2025
Evaluation of the systemic immune-inflammation index in relation to histological stages of celiac disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCeliac disease (CD) is an immune-mediated enteropathy characterized by histopathological changes, such as villous atrophy and chronic inflammation, often assessed using the Marsh classification. The systemic immune-inflammation index (SII), a novel inflammatory biomarker, has been increasingly investigated in chronic inflammatory diseases, including CD.
objectiveThis study aims to evaluate the relationship between SII and histopathological progression in CD, as classified by the Marsh scores, and to assess other hematological and inflammatory parameters.
methodsA retrospective analysis was conducted on 115 biopsy-confirmed CD patients from 2 hospitals between February 2022 and November 2023. Demographic, clinical, and laboratory data were analyzed, and SII values were calculated. Statistical comparisons were performed across Marsh stages.
resultsSII levels did not significantly differ among Marsh groups (p = 0.408). However, the Marsh Grade 3a group exhibited higher median SII values compared to others. Hemoglobin (Hb) levels showed significant differences across Marsh stages (p = 0.012), with a notable decrease in Marsh Grade 3c. Other parameters, such as ESR and CRP, showed no significant variation across groups.
conclusionWhile SII shows potential as an inflammatory marker, its limited association with histological stages suggests a need for larger, prospective studies to validate its utility in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.